Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Bevacizumab; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.
- 16 Feb 2018 Planned initiation date changed from 30 Jan 2018 to 30 Mar 2018.